{"filings":[{"id":982037,"accession_number":"0001193125-26-266687","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2026-06-11T11:11:50+00:00","items":["5.07"],"status":"ready","headline":"Biomea Fusion re-elects director nominees Erdtmann and Aguiar with majority withheld votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Rainer Erdtmann elected with 10,860,715 for, 12,956,116 withheld (20,107,625 broker non-votes).","Eric Aguiar elected with 9,553,344 for, 14,263,487 withheld (20,107,625 broker non-votes).","Ratification of Deloitte & Touche as auditor passed with 40,209,966 for, 3,561,734 against, 152,756 abstain.","Annual meeting held June 10, 2026; 43,924,456 shares present out of 72,299,440 entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":14962,"accession_number":"0001193125-26-217037","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2026-05-11T20:58:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion Q1 net loss $12.4M; cash $45.1M; icovamenib Phase II T2D data due Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.4M ($1.6M SBC) vs $29.3M in Q1 2025; cash, equivalents & restricted cash $45.1M at Mar 31, 2026; runway into Q1 2027.","R&D expenses $9.1M (down from $22.9M YoY); G&A $3.7M (down from $6.8M).","Icovamenib chronic tox studies completed; Phase II T2D trials COVALENT-211/-212 dosing; topline 26-week data expected Q4 2026.","Phase II T1D COVALENT-112: 52% C-peptide AUC increase at week 12 (200mg); preservation through week 52; plan for investigator-sponsored trial.","Phase I GLP-1 obesity trial (BMF-650, GLP-131) ongoing; initial 28-day weight data expected Q2 2026."],"consensus_eps_estimate":-0.2423,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96093,"accession_number":"0001193125-26-183710","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Biomea Fusion reports Phase 2 COVALENT-112 positive topline: 52% C-peptide increase in early T1D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In patients diagnosed within 3 years, icovamenib 200mg QD for 12 weeks increased mean C-peptide AUC by 52% (p<0.001, n=5) at Week 12; effect sustained with ~7% decline from baseline at Week 52.","Dose response observed; longer-standing T1D (3-15 years) preserved C-peptide through Week 52 with only modest decline.","Company plans Phase 2 trial with extended dosing (6-12 months) plus immunosuppressant, to start H2 2026 at four U.S. academic centers.","Study enrollment interrupted due to FDA clinical hold (resolved); data reflects about half intended population; no placebo control completed.","Icovamenib generally well tolerated; comprehensive data to be presented at ADA Scientific Sessions in June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109692,"accession_number":"0001193125-26-121811","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion reports FY2025 net loss of $61.8M; cash runway into Q1 2027; initiates Phase II trials in diabetes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.8M for FY2025 vs $138.4M in FY2024; R&D expenses decreased 47% to $62.0M.","Cash and equivalents $56.2M as of Dec 31, 2025; projected cash runway into Q1 2027.","Initiated Phase II trials COVALENT-211 and COVALENT-212 for icovamenib in type 2 diabetes; topline data expected Q4 2026.","Phase I trial GLP-131 (BMF-650) for obesity initiated; initial 28-day weight reduction data expected Q2 2026.","Positive 52-week data from COVALENT-111: 1.2% mean HbA1c reduction maintained 9 months off therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109691,"accession_number":"0001193125-26-068375","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biomea Fusion updates corporate presentation; no specific data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted an updated corporate presentation to its investor website on February 25, 2026.","Presentation furnished as Exhibit 99.1 via 8-K; no financial or clinical milestones disclosed in the filing.","Filing is a routine Regulation FD disclosure; no material new information contained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109690,"accession_number":"0001193125-26-012908","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Biomea Fusion holds JPM conference presentation; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presented at 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026; presentation posted to website.","Filed updated corporate presentation (Ex. 99.2) for investor use; 8-K body contains no specific financial or pipeline updates.","Forward-looking statements about clinical programs, but no new data, guidance, or milestones announced in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126207,"accession_number":"0001193125-25-264631","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Q3 net loss $16.4M (down 50% YoY); cash $47M; advances icovamenib and BMF-650","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.4M for Q3 2025 vs $32.8M in Q3 2024; R&D expenses down ~47% YoY.","Cash, cash equivalents $47M as of Sep 30, 2025; raised ~$68M in two public offerings extending runway into Q1 2027.","Icovamenib Phase II COVALENT-111: 1.5% mean HbA1c reduction at Week 52 in severe insulin-deficient T2D patients (p=0.01).","BMF-650 (oral GLP-1 RA) dosed first patient in Phase I; 28-day weight reduction data expected H1 2026.","Workforce reduced to ~40 employees as part of operational streamlining."],"consensus_eps_estimate":-0.2609,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126206,"accession_number":"0001193125-25-233614","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Biomea Fusion prices $25M public offering of common stock and warrants at $2.05/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11,195,121 shares + 1,000,000 pre-funded warrants, each paired with a warrant to buy one share at $2.50.","Combined price $2.05 per share+ warrant, $2.0499 per pre-funded warrant+ warrant; gross proceeds ~$25M.","Net proceeds estimated at $23.05M; closing expected October 8, 2025.","Underwriters granted 30-day option for up to 1,829,268 additional shares/warrants, partially exercised for warrants.","Jefferies sole bookrunner; H.C. Wainwright lead manager; shelf registration effective August 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126205,"accession_number":"0001193125-25-231903","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biomea Fusion reports 52-week Phase II COVALENT-111 data: HbA1c reductions up to 1.5% in severe insulin-deficient T2D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In severe insulin-deficient T2D patients (n=10), icovamenib achieved durable HbA1c reduction of 1.2% (p=0.01) through Week 52 after 12 weeks dosing.","Best result in Arm B (n=6): mean HbA1c reduction of 1.5% (p=0.01); no treatment-related serious adverse events.","In patients on GLP-1 therapy not at glycemic targets (n=11), icovamenib added 1.3% HbA1c reduction (p=0.05) sustained to Week 52.","Phase IIb trial (COVALENT-211) in severe insulin-deficient T2D expected to start Q4 2025; Phase II with GLP-1 (COVALENT-212) also Q4.","Food Effect Study (COVALENT-121) ongoing, expected completion by December 2025; oral GLP-1 RA (BMF-650) Phase I data anticipated H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142949,"accession_number":"0000950170-25-103023","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion Q2 net loss narrows to $20.7M, raises $42.8M, pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.7M (Q2 2025) vs $37.3M (Q2 2024); R&D expenses halved to $16.6M.","Raised ~$42.8M gross from public offering; cash runway extended into H2 2026.","Icovamenib at ADA 2025: durable HbA1c reduction, enhanced beta-cell function; combo with semaglutide showed superior glycemic control and weight loss with lean mass preservation.","BMF-650 achieved up to 15% weight loss in obese monkeys; IND submission on track for H2 2025.","Workforce reduced; quarterly expenses expected ~40% lower; oncology program BMF-500 ended, seeking partnerships."],"consensus_eps_estimate":-0.5412,"consensus_eps_actual":-1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142948,"accession_number":"0001193125-25-163815","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Biomea Fusion appoints Julianne Averill to board; Bihua Chen resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bihua Chen resigned as Class I director and Compensation Committee chair, effective July 22, 2025; no dispute.","Julianne Averill appointed as Class III director and Audit Committee member, effective same date.","Averill receives an option with $360,000 Black-Scholes grant value, vesting monthly over 3 years.","Averill is Managing Director at Danforth Advisors, CPA, with over 20 years in life sciences and digital health.","Chen served over four years; company thanks her for dedicated service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161025,"accession_number":"0001193125-25-143747","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Biomea Fusion closes $37.1M offering of 20M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 19.45M shares, 550K pre-funded warrants, and 20M common stock warrants at $2.00 per unit.","Net proceeds estimated at $37.1M; up to $42.7M if underwriters exercise 3M-share option in full.","Common stock warrants have $2.50 exercise price and expire 18 months from issuance.","Offering closed June 20, 2025; Jefferies LLC acted as representative of the underwriters.","Shares and warrants issued under effective shelf registration statement on Form S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161024,"accession_number":"0001193125-25-142830","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Biomea Fusion prices $40M public offering of 19.45M shares and warrants at $2.00/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 19.45M common shares and 19.45M accompanying warrants; 550K pre-funded warrants for certain investors.","Combined price $2.00 per share + warrant, $1.9999 per pre-funded warrant + warrant; gross proceeds ~$40M.","Common stock warrants exercisable at $2.50/share, expire 18 months from issuance; pre-funded warrants at $0.0001.","Expected close June 20, 2025; net proceeds ~$37.1M ($42.7M if underwriter option exercised in full).","Jefferies acting as sole book-runner; proceeds for general corporate purposes and clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161023,"accession_number":"0001193125-25-142126","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BMF-650 preclinical shows 12-15% weight loss in obese monkeys; IND on track H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["28-day study in 15 obese cynomolgus monkeys; oral BMF-650 at 10 or 30 mg/kg daily.","Weight loss of 12% (10 mg/kg) and 15% (30 mg/kg) from baseline at Day 28.","Daily food intake reduced to 35g (10 mg/kg) and 16g (30 mg/kg) vs 109g for vehicle.","IND submission for BMF-650 on track for second half of 2025.","Full preclinical data set planned for upcoming medical conference presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161022,"accession_number":"0001193125-25-140718","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomea Fusion annual meeting: directors elected, auditor ratified, liability amendment fails","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Class I directors Bihua Chen, Elizabeth Faust, and Sumita Ray with ~13.2M votes each.","Ratified Deloitte & Touche as independent auditor for FY2025 (22.6M for, 3.2M against).","Officer liability limitation amendment not approved; 13.6M for, 4.5M against, 7.7M broker non-votes.","Adjournment proposal to solicit additional proxies on Proposal 3 approved (13.4M for, 4.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161021,"accession_number":"0000950170-25-063523","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion Q1 loss $29.3M; realigns on diabetes/obesity, cuts workforce 35%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $29.3M ($36.2M cash); cash runway extended into Q4 2025.","Strategic realignment: 35% workforce reduction; focus on icovamenib and oral GLP-1 BMF-650.","R&D expenses $22.9M (down from $33.8M YoY); G&A $6.8M (down from $7.3M).","Phase II COVALENT-111 52-week T2D data expected H2 2025; Type-C meeting with FDA planned.","Interim CEO Mick Hitchcock appointed March 2025; oncology BMF-500 partnership exploration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179223,"accession_number":"0000950170-25-047755","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion Q4 net loss $29.3M; cash drops to $58.6M; interim CEO appointed, pivots to diabetes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.3M for Q4 2024 ($34.9M in Q4 2023); FY net loss $138.4M vs $117.3M.","Cash reserves $58.6M at Dec 31, 2024, down from $177.2M a year earlier.","Mick Hitchcock appointed interim CEO; all oncology trials terminated, focus shifts to diabetes/obesity.","Icovamenib in severe insulin-deficient T2D: 1.47% HbA1c reduction at Week 26; FDA meeting planned H1 2025.","BMF-650 (oral GLP-1 RA) IND submission planned H2 2025; preclinical appetite suppression data reported."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179222,"accession_number":"0001193125-25-065564","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["3.01","5.02","7.01","9.01"],"status":"ready","headline":"Biomea Fusion CEO Thomas Butler out; Board member Mick Hitchcock named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Butler terminated as CEO, resigned as director and Chairman effective March 25, 2025.","Michael J.M. Hitchcock (Mick) appointed interim CEO; Rainer Erdtmann named principal financial officer.","Audit Committee now has only two members due to Hitchcock's resignation; Nasdaq cure period until March 25, 2026.","Hitchcock receives $633,000 base salary, 50% target bonus, and options for 350,000 shares at $2.52/share.","Press release cites positive Phase II data for icovamenib as company pursues diabetes therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179221,"accession_number":"0001193125-25-042468","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Franco Valle resigns effective March 7, 2025; no replacement named.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Franco Valle resigned as CFO, effective March 7, 2025.","No disagreements between Valle and the Company were cited.","Departure is unrelated to any financial or accounting operations.","No successor has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179220,"accession_number":"0001193125-25-007107","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion pivots to diabetes & obesity; icovamenib shows 1.5% HbA1c drop in insulin-deficient patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted 1.5% mean HbA1c reduction in severe insulin-deficient T2D patients after 12 weeks of icovamenib, sustained 14 weeks off treatment.","Placebo-adjusted 1.0% HbA1c reduction in patients uncontrolled on GLP-1 therapies, consistent with preclinical synergy with semaglutide.","100% of severely insulin-deficient patients on 100 mg icovamenib responded with durable HbA1c decline; no drug-related adverse events.","Company plans to end oncology studies, seek partnerships, and focus on two late-stage trials: Phase 2/3 in insulin-deficient T2D and Phase 2b combo with GLP-1.","Novel oral menin inhibitor designed to regenerate beta cells; FDA discussions expected to support late-stage development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195901,"accession_number":"0001193125-24-283008","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Biomea Fusion icovamenib Phase II meets primary endpoint; 1.47% HbA1c reduction in insulin-deficient T2D patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Best response in beta-cell deficient patients on antidiabetic agents: placebo-adjusted HbA1c reduction 1.47% at Week 26 (p=0.022) after 12 weeks dosing.","Arm B (100mg QD for 12 weeks) showed mean HbA1c reduction of 0.5% (p=0.012) in per protocol patients on one or more baseline therapy.","In insulin-deficient subtypes (SIDD/MARD), Arm B demonstrated mean HbA1c reduction of 1.05% (p=0.004).","Icovamenib well-tolerated: no AE-related discontinuations, no hypoglycemic events, no related serious adverse events.","Company plans to discuss data with FDA; 52-week readout anticipated in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195900,"accession_number":"0001193125-24-248083","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Biomea Fusion: icovamenib boosts GLP-1 therapy insulin secretion; new oral GLP-1 RA BMF-650 shows early promise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical ex vivo human islet data show icovamenib combined with tirzepatide or semaglutide more than doubles glucose-stimulated insulin secretion under hyperglycemic conditions.","Phase II COVALENT-211 study combining icovamenib with a GLP-1-based therapy planned to begin in 2025.","New oral small-molecule GLP-1 RA candidate BMF-650 exhibited higher bioavailability, less variable PK; estimated human dose ~100 mg once daily.","In cynomolgus monkeys, BMF-650 improved glucose control and significantly suppressed appetite over a six-day dosing period.","BMF-650 also enhanced glucose-stimulated insulin secretion in human donor islets, supporting potential for diabetes and obesity treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195899,"accession_number":"0000950170-24-118344","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion reports Q3 net loss of $32.8M; FDA lifts clinical hold on diabetes trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $88.3M as of Sep 30, 2024, down from $177.2M at Dec 31, 2023.","Net loss $32.8M for Q3 2024 vs $28.4M same period 2023; includes $4.7M stock-based comp.","FDA lifted clinical hold on COVALENT-111 (type 2 diabetes) and COVALENT-112 (type 1 diabetes) trials.","Topline Week 26 data for both trials expected in December 2024.","Announced third clinical candidate BMF-650 (oral GLP-1 RA); preclinical data to be shared Oct 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212177,"accession_number":"0001193125-24-227940","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on Biomea Fusion's BMF-219 for type 2 and type 1 diabetes trials","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted clinical hold on Phase I/II trials COVALENT-111 (type 2 diabetes) and COVALENT-112 (type 1 diabetes) as of Sept 26, 2024.","CEO stated safety signals from Phase 2a Escalation Study did not translate to Phase 2b Expansion Study; no confirmed serious liver injury.","Company expects to announce a third development candidate (oral GLP-1 agonist) in Q4 2024.","Topline Week 26 data from ~200-patient Phase 2b COVALENT-111 and Phase 2a COVALENT-112 (20 patients) expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212176,"accession_number":"0000950170-24-088581","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion Q2 net loss $37.3M; FDA clinical hold on diabetes trials; topline readouts on track for Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.3M in Q2 vs $24.9M YoY; cash $113.7M, down from $177.2M end of 2023.","FDA imposed full clinical hold on BMF-219 diabetes trials due to hepatotoxicity concerns.","Topline data from Phase 2b (type 2, ~195 pts) and Phase 2a (type 1, ~20 pts) still expected Q4 2024.","Third obesity program (oral GLP-1R agonist) to be announced Q3 2024.","Two COVALENT-101 cohorts (CLL, DLBCL) discontinued due to insufficient enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231082,"accession_number":"0001193125-24-160033","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomea Fusion annual meeting results: directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Thomas Butler elected with 17,146,384 votes for, 270,903 withheld; Michael Hitchcock elected with 12,664,859 for, 4,752,428 withheld.","Ratification of Deloitte & Touche as auditor for FY2024: 24,758,391 for, 54,281 against, 29,631 abstentions.","Broker non-votes on director election totaled 7,425,016 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231081,"accession_number":"0001193125-24-157310","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places full clinical hold on Biomea Fusion's BMF-219 diabetes trials due to liver enzyme elevations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Full clinical hold on Phase I/II COVALENT-111 and COVALENT-112 for BMF-219 in type 2 and type 1 diabetes.","FDA cited potential drug-induced hepatotoxicity; higher doses up to 400 mg may have contributed to liver enzyme elevations.","Most adverse events mild to moderate; no serious adverse reactions reported to date with BMF-219.","Company continues data collection during hold; collaborating with FDA to resolve clinical hold quickly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231080,"accession_number":"0000950170-24-052121","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion Q1 2024 net loss $39.1M; cash $145.3M; positive diabetes clinical data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.1M in Q1 2024 (incl. $5.0M stock comp) vs $29.1M in Q1 2023; R&D expenses rose to $33.8M.","Cash, equivalents and restricted cash $145.3M at March 31, 2024, down from $177.2M at Dec 31, 2023.","In type 2 diabetes COVALENT-111, 20%/36% of 100mg/200mg cohorts achieved durable HbA1c ≥1.0% reduction off therapy at 26 weeks.","In type 1 diabetes COVALENT-112, first two patients showed improved beta-cell function (C-peptide Index) after BMF-219; well tolerated.","Plan to report Week 26 data from >200 T2D patients (~40 T1D patients) in 2024; expect lower opex in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231079,"accession_number":"0001193125-24-083352","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion reports initial data from first two T1D patients dosed with BMF-219; C-peptide increased","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Patient 1 (200 mg): fasting C-peptide +57% at week 4, +80% at week 8; MMTT C-peptide index AUC +12% and +40%.","Patient 2 (100 mg): fasting C-peptide +16% at week 4; MMTT C-peptide index AUC +30%; reduced daily insulin usage.","BMF-219 well tolerated in both patients; no safety signals reported.","Open-label portion of COVALENT-112 (n=40) with 12-week dosing data expected in 2024.","First type 2 diabetes patient in COVALENT-111 discontinued metformin after week 40 with improved glycemic control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231078,"accession_number":"0000950170-24-039304","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion reports Q4 2023 net loss $34.9M; cash $177.2M; clinical data readouts expected 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $117.3M for FY 2023 vs $81.8M in 2022; Q4 loss $34.9M vs $25.3M.","Cash, equivalents, restricted cash, investments $177.2M at Dec 31, 2023, up from $113.4M year earlier.","R&D expenses $102.5M for FY 2023, up from $62.7M, driven by BMF-219 and BMF-500 clinical costs.","Phase 2 type 2 diabetes data showed continued glycemic control 5 months off therapy; expansion cohort of 216 patients underway.","Phase 2 type 1 diabetes study (COVALENT-112) initiated; initial data readout anticipated in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249476,"accession_number":"0001193125-24-062154","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion presents COVALENT-111 data: up to 1.4% placebo-adjusted HbA1c reduction at Week 26 off therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted mean HbA1c reduction up to 1.4% at Week 26 after 28-day BMF-219 treatment.","100mg and 200mg dose levels selected for expansion phase; 12-week dosing, follow-up to Week 52.","No serious adverse events or study discontinuations; no symptomatic hypoglycemia.","Expansion phase enrolling on schedule; initial 26-week data expected 2H24.","Biomea plans to announce COVALENT-112 T1D update in Q4 2023 earnings release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249475,"accession_number":"0001193125-24-005929","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion presents at J.P. Morgan Healthcare Conference; slides filed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presented business update at 42nd Annual J.P. Morgan Healthcare Conference on Jan 9, 2024.","Presentation slides filed as Exhibit 99.1 but full content not provided in this extract.","No specific financial or operational data available from the filing body.","Investors should review the full presentation on the company's website or SEC EDGAR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266923,"accession_number":"0000950170-23-056335","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion reports Q3 net loss of $28.4M, advances diabetes and oncology pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.4M for Q3 2023 vs $22.9M in Q3 2022; cash of $199.5M as of Sep 30, 2023.","COVALENT-111 expansion cleared; 84% of patients showed HbA1c reduction at Week 4; enrollment in ~200 type 2 diabetics.","IND cleared for COVALENT-112 (BMF-219) in type 1 diabetes; enrollment of 150 adults expected to start in Q4 2023.","Initial AML data: 2 CRs out of 5 patients with menin-dependent mutations at Dose Level 4; BMF-500 first patient dosed.","Appointed Juan Pablo Frías, M.D., as Chief Medical Officer to oversee diabetes clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284208,"accession_number":"0000950170-23-035939","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion Q2 2023: positive diabetes & AML data; net loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diabetes: in Cohort 3 (100 mg BMF-219 QD), mean HbA1c reduction of 1.49% at Week 12, 62% greater than at end of 4-week dosing.","60% of Cohort 3 patients achieved HbA1c ≤7% at Week 12 vs 30% at Week 4; no severe TEAEs off treatment.","Oncology: 2 complete responses out of 5 relapsed/refractory AML patients carrying menin-dependent mutations at Dose Level 4.","Cash $223.3M as of June 30, 2023; net loss $24.9M in Q2 2023 vs $17.3M in Q2 2022.","Initiated Phase I for BMF-500 (COVALENT-103), a third-generation covalent FLT3 inhibitor."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284207,"accession_number":"0001193125-23-193428","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BMF-219 induces 2 complete responses in 5 AML patients with menin mutations in Phase I trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2 of 5 relapsed/refractory AML patients with menin-dependent mutations achieved CRs at Dose Level 4 (500mg or 125mg QD).","CRs observed within first two 28-day cycles; both patients continue on BMF-219 treatment.","No dose-limiting toxicities or QTc prolongation reported; generally well tolerated.","Dose Level 5 enrollment commenced to explore optimal biological dose.","Biomea plans to present additional data at an upcoming medical conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303832,"accession_number":"0001193125-23-167884","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomea Fusion shareholders elect two Class II directors and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors elected: Rainer Erdtmann (16,369,686 for, 5,798,793 withheld) and Eric Aguiar, M.D. (16,248,905 for, 5,919,574 withheld); 4,235,582 broker non-votes.","Ratification of Deloitte & Touche as independent auditor for FY 2023 approved with 26,375,250 for, 7,575 against, 21,236 abstentions; no broker non-votes.","Total shares entitled to vote: 35,648,288; shares present or proxy: 26,404,061."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303831,"accession_number":"0001193125-23-132621","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion receives FDA clearance for IND of BMF-500 in relapsed/refractory acute leukemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for BMF-500, a novel covalent FLT3 inhibitor, to begin Phase I trial COVALENT-103 in adult patients with relapsed or refractory acute leukemia.","BMF-500 is the second investigational compound from Biomea's FUSION System to enter the clinic.","Preclinical data: BMF-500 showed ~20-fold greater potency than gilteritinib and >50-fold greater than reversible menin/MLL inhibitors in AML cell lines.","Combination of BMF-500 and BMF-219 showed greater than additive cell killing in acute leukemia cell lines and patient samples.","BMF-500 designed for high target selectivity with minimal off-target liabilities; potential for combinations with standard of care or BMF-219."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303830,"accession_number":"0000950170-23-016684","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion reports Q1 net loss $29.1M, cash $86.7M plus $172.5M offering; positive Phase II diabetes data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.1M vs $16.4M in Q1 2022; R&D expense $24.4M (up from $11.4M).","Cash $86.7M at Mar 31, 2023; plus $172.5M gross from April offering to ≈$259M total.","COVALENT-111 Phase II Cohort 3 (100 mg): 89% of patients had HbA1c reduction, 56% had ≥1% reduction.","IND cleared for BMF-500; Phase I COVALENT-103 for FLT3-mutant acute leukemias to start enrolling.","Initial AML/ALL data from COVALENT-101 expected in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303829,"accession_number":"0001193125-23-089530","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Biomea Fusion prices upsized $150M public offering of 5M shares at $30; net proceeds ~$161.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,000,000 shares at $30.00 per share; gross proceeds of $150.0 million.","Underwriters exercised 30-day option to purchase additional 750,000 shares in full.","Net proceeds of approximately $161.6 million after underwriting discounts and expenses.","Proceeds to fund clinical development of BMF-219 (menin inhibitor) and BMF-500 (FLT3 inhibitor).","J.P. Morgan and Citigroup acted as joint book-running managers; closing on April 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323527,"accession_number":"0001193125-23-082314","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Biomea Fusion reports 89% response rate and 1% median HbA1c reduction at 4 weeks for BMF-219 in T2DM Phase II","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 3 (100 mg BMF-219 without food, n=9) showed 89% response rate, median HbA1c reduction of -1.0% at day 28.","56% of Cohort 3 patients achieved >=1.0% HbA1c reduction; placebo (n=4) had median reduction of -0.1% to -0.15%.","BMF-219 was well-tolerated; no discontinuations, serious AEs, or severe AEs across healthy volunteers and T2DM cohorts.","Company plans to explore additional dosing periods >4 weeks and potential utility in type 1 diabetes.","Dose escalation continues; negative food effect observed (3-fold exposure difference between fed and fasted cohorts)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323526,"accession_number":"0000950170-23-010286","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion reports FY2022 net loss of $81.8M; cash $113.4M; clinical progress across three trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.3M in Q4 2022 ($14.7M in Q4 2021); full-year loss $81.8M vs $41.6M in 2021.","Cash, equivalents, and investments $113.4M at Dec 31, 2022, down from $175.7M a year earlier.","R&D expense $62.7M in FY2022 vs $28.0M; increase driven by clinical/preclinical development of BMF-219 and BMF-500.","BMF-219 advanced in three trials: COVALENT-101 (liquid tumors), COVALENT-102 (KRAS-mutant solid tumors), COVALENT-111 (type 2 diabetes); initial diabetes data reported March 2023.","IND for BMF-500 (FLT3 inhibitor) on track for H1 2023; third development candidate from FUSION platform expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323525,"accession_number":"0001193125-23-007186","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion details 2023 milestones: AML/ALL data, KRAS trial, diabetes data, BMF-500 IND","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Plan to present initial COVALENT-101 data (BMF-219 in AML/ALL) in H1 2023; first patient in COVALENT-102 (KRAS solid tumors) dosed Jan 2023.","IND for BMF-500 (FLT3 inhibitor) expected in H1 2023 for COVALENT-103 trial in acute leukemia.","Phase II COVALENT-111 (BMF-219 in Type 2 diabetes) initial data from first two cohorts by end of Q1 2023.","Third development candidate from FUSION platform to be announced in H1 2023.","BMF-219 is first menin inhibitor in clinical development for solid tumors and diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341542,"accession_number":"0001193125-22-307318","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion receives FDA IND clearance for BMF-219 in type 2 diabetes; expands COVALENT-111 to US sites","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for BMF-219 (covalent menin inhibitor) in type 2 diabetes; will activate US sites in ongoing COVALENT-111 study.","Phase I portion completed with favorable safety, PK, and PD profile.","Phase II portion evaluating BMF-219's ability to restore beta-cell health and long-term glycemic control.","Initial Phase II data expected in first half of 2023.","Company to host investor conference call on December 15, 2022 at 4 PM EST."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341541,"accession_number":"0001193125-22-303796","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion presents preclinical data for BMF-500 at ASH; IND on track for H1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BMF-500 demonstrated picomolar affinity to FLT3 mutations, including ITD and TKD.","Complete tumor regression in FLT3-ITD xenograft models; effect maintained without continuous exposure.","Three-hour pulse of BMF-500 outperformed continuous gilteritinib exposure in cell killing.","IND submission for BMF-500 planned for first half of 2023.","BMF-500 showed high selectivity with minimal off-target cytotoxicity across 20 cancer cell lines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341540,"accession_number":"0001193125-22-292554","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2022-11-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Biomea Fusion enters ATM equity distribution agreement for up to $100M with Piper Sandler","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered equity distribution agreement with Piper Sandler for up to $100M ATM offering of common stock.","Piper Sandler commission up to 3.0%; no minimum sales required under agreement.","Shares sold under existing S-3 registration (333-267884) filed Oct 14, 2022.","ATM sales on Nasdaq; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341539,"accession_number":"0000950170-22-022598","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biomea Fusion Q3 net loss $22.9M, cash $133.8M; advances BMF-219 into KRAS solid tumors and T2D","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.9M in Q3 2022 ($12.6M in Q3 2021); cash & investments $133.8M vs $175.7M year-end 2021.","BMF-219 Phase I COVALENT-101 enrolling four liquid tumor cohorts; Cohort I at Dose Level 3, no DLTs; initial data H1 2023.","COVALENT-102 (Phase I/Ib) initiated for KRAS-mutated solid tumors (NSCLC, CRC, PDAC) under FDA clearance Oct 2022.","COVALENT-111 (Phase I/II) dosed first type 2 diabetes patient; healthy volunteer portion completed with no safety signals.","Expect IND submissions for BMF-500 (FLT3 inhibitor) and BMF-219 in T2D in H1 2023 and year-end 2022, respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":1235000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341538,"accession_number":"0001193125-22-274908","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion doses first T2D patient in Phase II of BMF-219; Phase I completed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient with type 2 diabetes dosed in Phase II portion of COVALENT-111 (Phase I/II) of BMF-219.","Phase I healthy volunteer portion completed; BMF-219 well tolerated with favorable PK/PD profile.","BMF-219 is the first menin inhibitor to reach clinic for type 2 diabetes; aims to restore beta cells.","Initial Phase II data expected in first half of 2023; IND filing with FDA on track for Q4 2022.","Preclinical data showed BMF-219 ability to restore beta cell mass in animal models of T2D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341537,"accession_number":"0001193125-22-264447","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2022-10-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion announces FDA IND clearance for BMF-219 in KRAS solid tumors; Phase I/Ib trial to begin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for BMF-219 to initiate Phase I/Ib trial (COVALENT-102) in KRAS-mutant NSCLC, CRC, and PDAC.","BMF-219 is the first menin inhibitor to enter clinical trials for solid tumors.","Preclinical data showed pan-KRAS activity across G12C, G12D, G12V, and G13D mutations.","Company already has COVALENT-101 Phase I trial in blood cancers underway.","KRAS mutations present in 25-35% of NSCLC, 35-45% of CRC, and ~90% of PDAC patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358487,"accession_number":"0001193125-22-249373","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2022-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion EASD data: BMF-219 increases beta cell mass in human islets, improves glycemic control in rat T2D models","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BMF-219 increased beta cell mass in ex vivo human donor islets, first such translational data presented.","In ZDF rats, OGTT AUC reduced 54% vs vehicle (p<0.001) during treatment; 40% reduction maintained 2 weeks after washout (p<0.05).","In STZ rats, BMF-219 nearly doubled HOMA-B (+96%) and restored non-fasting glucose to near-normal by day 8.","BMF-219 reduced blood lipemic levels and body weight in both ZDF and STZ rat models.","Company remains on track to file IND for BMF-219 in type 2 diabetes in second half of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358486,"accession_number":"0001193125-22-248476","cik":1840439,"company_name":"Biomea Fusion, Inc.","ticker":"BMEA","form_type":"8-K","filed_at":"2022-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biomea Fusion reports BMF-219 preclinical data: HbA1c reduction of 3.5% vs. liraglutide's 1.7% in T2D rat model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BMF-219 lowered HbA1c by 3.5% vs. liraglutide 1.7% in ZDF rat model; effect maintained through 2-week drug washout.","BMF-219 restored HOMA-B index to normal range (>201) over 4 weeks, indicating improved beta-cell function.","BMF-219 treatment resulted in 13% body weight reduction over 4 weeks and lowered total cholesterol and triglycerides.","Company reaffirms IND submission for BMF-219 in type 2 diabetes in second half of 2022.","Data presented at EASD Annual Meeting on September 20, 2022 in Stockholm, Sweden."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":98688734.19485292,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-22T23:59:59+00:00|358486"}